SI20108B - A controlled release formulation for poorly soluble basic drugs - Google Patents
A controlled release formulation for poorly soluble basic drugs Download PDFInfo
- Publication number
- SI20108B SI20108B SI9720096A SI9720096A SI20108B SI 20108 B SI20108 B SI 20108B SI 9720096 A SI9720096 A SI 9720096A SI 9720096 A SI9720096 A SI 9720096A SI 20108 B SI20108 B SI 20108B
- Authority
- SI
- Slovenia
- Prior art keywords
- composition
- alginate
- sodium
- salt
- water
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1997/010705 WO1998056357A1 (en) | 1995-12-19 | 1997-06-11 | A controlled release formulation for poorly soluble basic drugs |
Publications (2)
Publication Number | Publication Date |
---|---|
SI20108A SI20108A (sl) | 2000-06-30 |
SI20108B true SI20108B (en) | 2001-12-31 |
Family
ID=22261117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI9720096A SI20108B (en) | 1997-06-11 | 1997-06-11 | A controlled release formulation for poorly soluble basic drugs |
Country Status (4)
Country | Link |
---|---|
NO (1) | NO310095B1 (no) |
SI (1) | SI20108B (no) |
SK (1) | SK282427B6 (no) |
WO (1) | WO1998056357A1 (no) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3668000A (en) * | 1999-04-29 | 2000-11-17 | Russinsky Limited | Compounds |
EP1118333A1 (en) * | 2000-01-18 | 2001-07-25 | Eurand International S.P.A. | Compositions with enhanced oral bioavailability |
UA76967C2 (uk) * | 2000-11-27 | 2006-10-16 | Сандоз Аг | Азитроміцин у формі моногідрату, фармацевтична композиція та спосіб його одержання |
BR0308990A (pt) * | 2002-04-03 | 2005-01-04 | Ranbaxy Lab Ltd | Composição farmacêutica de eritromicina e seus derivados com sabor mascarado e processo de sua preparação |
SI21300A (sl) * | 2002-10-08 | 2004-04-30 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Farmacevtske formulacije z alginati |
CN100336511C (zh) * | 2002-11-15 | 2007-09-12 | 江苏豪森药业股份有限公司 | 口服罗红霉素控释制剂 |
PL1638529T3 (pl) * | 2003-06-16 | 2017-03-31 | Andrx Pharmaceuticals, Llc. | Kompozycja doustna o przedłużonym uwalnianiu |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
WO2016033556A1 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS |
WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
JP2020503269A (ja) | 2016-11-28 | 2020-01-30 | リポカイン インコーポレーテッド | 経口ウンデカン酸テストステロン療法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60163823A (ja) * | 1984-02-03 | 1985-08-26 | Taisho Pharmaceut Co Ltd | 経口投与製剤 |
EP0188040B1 (en) * | 1985-01-11 | 1991-08-14 | Abbott Laboratories Limited | Slow release solid preparation |
US5705190A (en) * | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
-
1997
- 1997-06-11 WO PCT/US1997/010705 patent/WO1998056357A1/en active Application Filing
- 1997-06-11 SI SI9720096A patent/SI20108B/sl unknown
- 1997-06-11 SK SK1612-99A patent/SK282427B6/sk not_active IP Right Cessation
-
1999
- 1999-12-13 NO NO996161A patent/NO310095B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
SI20108A (sl) | 2000-06-30 |
WO1998056357A1 (en) | 1998-12-17 |
NO996161D0 (no) | 1999-12-13 |
NO996161L (no) | 1999-12-13 |
NO310095B1 (no) | 2001-05-21 |
SK161299A3 (en) | 2000-05-16 |
SK282427B6 (sk) | 2002-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI20108B (en) | A controlled release formulation for poorly soluble basic drugs | |
RU97112089A (ru) | Твердая фармацевтическая композиция с регулируемым высвобождением лекарственного средства | |
UA40663C2 (uk) | Тверда фармацевтична композиція з регульованим вивільненням лікарського засобу для орального вживання | |
US5646131A (en) | Method for solubilizing drugs using cyclodextrins and carboxylic acids | |
JPH0434966B2 (no) | ||
JPH0229052B2 (no) | ||
RU2333745C2 (ru) | Композиции с контролируемым высвобождением | |
HRP20010243B1 (en) | Compositions containing diphosphonic acids | |
PL295329A1 (en) | Method of improving oral administration applicability of a biological medication substance: dideoxypurin nucleoside | |
Zuckerman | The newer macrolides: azithromycin and clarithromycin | |
ES2235834T3 (es) | Matriz directamente comprimible para la liberacion controlada de dosis diarias unicas de claritromicina. | |
CA2383212A1 (en) | Controlled release oral dosage suitable for oral administration | |
HK1058622A1 (en) | Pharmaceutical form of administration for peptides, method for its production and use | |
KR19980702689A (ko) | 알긴산나트륨 및 중탄산칼륨을 포함하는 액체 수성 약제학적조성물 | |
CA2083385C (en) | Sustained release suppository | |
CA2380757A1 (en) | Pharmaceutical agent comprising a benzamide derivative as active ingredient | |
JPH1192402A (ja) | 製剤組成物及びその製造方法 | |
SK42999A3 (en) | Aqueous liquid pharmaceutical formulation, process for the preparation and use thereof | |
AU749509B2 (en) | Use of triclosan for the treatment of helicobacter pylori infections | |
Vandamme et al. | Controlled release of levamisole from poly-(ε-caprolactone) matrices II. Effects of water-soluble polymer and iron powder incorporated into the matrices | |
Watson | Bioavailability and bioinequivalence of drug formulations in small animals | |
US20050260263A1 (en) | Sustained release formulation for sparingly soluble main drugs | |
EA199900938A1 (ru) | Способ приготовления стабильного фармацевтического состава с фиксированной дозировкой из антиинфекционного агента/агентов и микроорганизмов в качестве активных ингредиентов | |
US20040067253A1 (en) | Pharmaceutical preparation, method for its production as well as its use | |
YU25297A (en) | A controlled release formulation for poorly soluble basic drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
IF | Valid on the prs date | ||
SP73 | Change of data on owner |
Owner name: BGP PRODUCTS OPERATIONS GMBH; CH Effective date: 20160404 |